Literature DB >> 10768680

Antimicrobial use in defined populations of infants and young children.

J A Finkelstein1, J P Metlay, R L Davis, S L Rifas-Shiman, S F Dowell, R Platt.   

Abstract

BACKGROUND: Antimicrobial overprescribing contributes to bacterial resistance, but data on use in infants and young children are limited.
OBJECTIVES: To assess antimicrobial use in a defined population of infants and young children and to determine diagnosis-specific prescribing rates for common infections. DESIGN AND
SETTING: Retrospective cohort study of children served by 44 practices affiliated with 2 managed care organizations. PATIENTS: Children aged 3 months to 72 months enrolled in either health plan between September 1, 1994, and August 31, 1996. ANALYSIS: Rates of antimicrobial use were calculated as the number of pharmacy dispensings divided by the number of person-years of observation contributed to the cohort in 2 age groups (3 to <36 months and 36 to <72 months). Other outcomes included the distribution of diagnoses associated with antimicrobial dispensing and population-based rates of diagnosis of common acute respiratory tract illnesses.
RESULTS: A total of 46477 children contributed 59710 person-years of observation across the 2 health plans. Rates of antimicrobial dispensing for children aged 3 to 36 months were 3.2 and 2.1 dispensings per person-year in the 2 populations. A substantial fraction of younger children (35% in population A and 23% in population B) received 4 or more antimicrobial prescriptions in a single year. For children aged 36 to 72 months, the dispensing rates for the 2 populations were 2.0 and 1.5 antimicrobials per person-year. We found significant differences in rates between the populations studied and a decrease in use at all sites from 1995 to 1996. The diagnosis of otitis media accounted for 56% of antimicrobial drugs dispensed to children aged 3 to 36 months and 40% of those dispensed to children aged 36 to 72 months. Antimicrobial prescribing for colds and upper respiratory tract infections, bronchitis, and sinusitis was less frequent than previously reported but accounted for 10% to 14% of antimicrobial drugs dispensed.
CONCLUSIONS: In these populations, otitis media accounted for the largest number of antimicrobial agents dispensed to children younger than 6 years. Clearly inappropriate indications such as cold, upper respiratory tract infection, and bronchitis accounted for smaller fractions of antimicrobial use but may be most amenable to change. However, interventions that encourage use of strict criteria for diagnosis and treatment of otitis media will likely have the greatest impact on overall antimicrobial exposure. Monitoring defined populations longitudinally will allow assessment of the effectiveness of such national and local initiatives.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10768680     DOI: 10.1001/archpedi.154.4.395

Source DB:  PubMed          Journal:  Arch Pediatr Adolesc Med        ISSN: 1072-4710


  34 in total

1.  Antibiotic prescribing trends in an omani paediatric population.

Authors:  Khalid Al-Balushi; Fatma Al-Ghafri; Fatma Al-Sawafi; Ibrahim Al-Zakwani
Journal:  Sultan Qaboos Univ Med J       Date:  2014-10-14

2.  Variability in antibiotic use at children's hospitals.

Authors:  Jeffrey S Gerber; Jason G Newland; Susan E Coffin; Matt Hall; Cary Thurm; Priya A Prasad; Chris Feudtner; Theoklis E Zaoutis
Journal:  Pediatrics       Date:  2010-11-15       Impact factor: 7.124

Review 3.  Breastfeeding and otitis media: a review of recent evidence.

Authors:  Sheryl W Abrahams; Miriam H Labbok
Journal:  Curr Allergy Asthma Rep       Date:  2011-12       Impact factor: 4.806

4.  Clinical, social and relational determinants of paediatric ambulatory drug prescriptions due to respiratory tract infections in Italy.

Authors:  Marta Luisa Ciofi degli Atti; Marco Massari; Antonino Bella; Delia Boccia; Antonietta Filia; Stefania Salmaso
Journal:  Eur J Clin Pharmacol       Date:  2006-10-05       Impact factor: 2.953

5.  Treatment of acute otitis media in children under 2 years of age.

Authors:  Alejandro Hoberman; Jack L Paradise; Howard E Rockette; Nader Shaikh; Ellen R Wald; Diana H Kearney; D Kathleen Colborn; Marcia Kurs-Lasky; Sonika Bhatnagar; Mary Ann Haralam; Lisa M Zoffel; Carly Jenkins; Marcia A Pope; Tracy L Balentine; Karen A Barbadora
Journal:  N Engl J Med       Date:  2011-01-13       Impact factor: 91.245

6.  Shortened Antimicrobial Treatment for Acute Otitis Media in Young Children.

Authors:  Alejandro Hoberman; Jack L Paradise; Howard E Rockette; Diana H Kearney; Sonika Bhatnagar; Timothy R Shope; Judith M Martin; Marcia Kurs-Lasky; Susan J Copelli; D Kathleen Colborn; Stan L Block; John J Labella; Thomas G Lynch; Norman L Cohen; MaryAnn Haralam; Marcia A Pope; Jennifer P Nagg; Michael D Green; Nader Shaikh
Journal:  N Engl J Med       Date:  2016-12-22       Impact factor: 91.245

7.  Reduced-Concentration Clavulanate for Young Children with Acute Otitis Media.

Authors:  Alejandro Hoberman; Jack L Paradise; Howard E Rockette; Jong-Hyeon Jeong; Diana H Kearney; Sonika Bhatnagar; Timothy R Shope; Gysella Muñiz; Judith M Martin; Marcia Kurs-Lasky; MaryAnn Haralam; Marcia A Pope; Jennifer P Nagg; Wenchen Zhao; Mohammad Kowser Miah; Jan Beumer; Raman Venkataramanan; Nader Shaikh
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

8.  Treatment of Streptococcus pneumoniae otitis media in a chinchilla model by transtympanic delivery of antibiotics.

Authors:  Rong Yang; Vishakha Sabharwal; Nadya Shlykova; Obiajulu S Okonkwo; Stephen I Pelton; Daniel S Kohane
Journal:  JCI Insight       Date:  2018-10-04

9.  Infant antibiotic exposures and early-life body mass.

Authors:  L Trasande; J Blustein; M Liu; E Corwin; L M Cox; M J Blaser
Journal:  Int J Obes (Lond)       Date:  2012-08-21       Impact factor: 5.095

Review 10.  Antibiotic prescription and prevalence rate in the outpatient paediatric population: analysis of surveys published during 2000-2005.

Authors:  Alessandra Rossignoli; Antonio Clavenna; Maurizio Bonati
Journal:  Eur J Clin Pharmacol       Date:  2007-09-21       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.